Granted Patent
B2
US 11,739,074 · App. 17/088,848 · Granted Aug 29, 2023
Ras inhibitors
Inventors:
James Aggen (Burlingame, CA); G. Leslie Burnett (Redwood City, CA); Jennifer Pitzen (Fremont, CA); Adrian L. Gill (Atherton, CA); Elena S. Koltun (Foster City, CA); James Cregg (Belmont, CA); Andreas Buckl (San Francisco, CA); Anne V. Edwards (San Mateo, CA); John E. Knox (Emerald Hills, CA)
Assignee:
Revolution Medicines, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers. Exemplary Ras inhibitors include compounds of Formula I:
Claims (2)
1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of
2. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable excipient.
Assignments (3)
SECURITY INTEREST
Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 6, 2022
From: THOMAS, WILLIAM D.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 060412/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 14, 2021
From: AGGEN, JAMES; BURNETT, G. LESLIE; PITZEN, JENNIFER; GILL, ADRIAN L.; KOLTUN, ELENA S.; CREGG, JAMES; BUCKL, ANDREAS; EDWARDS, ANNE V.; SEMKO, CHRISTOPHER; GLIEDT, MICAH JAMES; KNOX, JOHN E.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 054926/0869 →
Cited By (5)